What if we assessed cognitive health
by
neurophysiology, not behavior?
Introducing VoxNeuro CORE
A leading-edge cognitive health assessment that uses established neuropsychological and cognitive tests in combination with EEG-based brain performance software to objectively score cognitive function.
EEG-BASED COGNITIVE BIOMARKERS
Fast, like MOCA
Thorough, like a full neuropsych battery
Quantitative measures, evaluated against a normative database
Broadly applicable, with medical necessity across 20+ clinical conditions
VoxNeuro CORE employs EEGs and established neuropsychological and cognitive tests.
5 mins
Patient setup
5 mins
Resting State Test
3.5 mins
Auditory Evoked
Potential Test
Potential Test
3.5 mins
Visual Evoked
Potential Test
Potential Test
10 mins
Attention and Concentration & Information Processing Test
8 mins
Memory Test
5 mins
Patient cleanup
Validated from end-to-end.
VoxNeuro IP: Patent US 11,278,230
Normative database validated across age and sex cohorts from 12-90
Built on a legacy of
ground breaking research
Thousands of articles on ERPs, validating EEG-based cognitive
biomarkers, including top researchers with NIH funding.1
1. Donoghue, Automated meta-analysis of the event-related potential (ERP) literature, 2021
OVERALL RESEARCH
VoxNeuro’s Industry-leading Research
←
→
Contact us to learn more about the foundational research in EEG-based
cognitive biomarkers.
We are witnessing an
unfolding brain health crisis.
Between a growing and aging population and
the impact of COVID-19, there is a greater need to assess
and manage brain health and wellness.
the impact of COVID-19, there is a greater need to assess
and manage brain health and wellness.
We are witnessing an
unfolding brain health crisis.
Between a growing and aging population and
the impact of COVID-19, there is a greater need to assess
and manage brain health and wellness.
the impact of COVID-19, there is a greater need to assess
and manage brain health and wellness.
TRAUMATIC BRAIN INJURIES
Approximately
2.5M
people visit the ER with TBIs each year2
COGNITIVE IMPAIRMENT
Approximately
13M
people in the US are living with mild cognitive impairment (MCI)3
TRENDS
An approximate increase
33%
in projected MCI cases among people in the US by 20303
2. Taylor et al. Traumatic Brain Injury–Related Emergency Department Visits, Hospitalizations, and Deaths — United States, 2007 and 2013. 2017
3. Rajan et al. Population Estimate of People with Clinical AD and Mild Cognitive Impairment in the United States (2020–2060). 2017
3. Rajan et al. Population Estimate of People with Clinical AD and Mild Cognitive Impairment in the United States (2020–2060). 2017
Contact us to learn more about how VoxNeuro can help you meet your patients' brain health needs.
Traditional cognitive health assessments have their place, but these approaches have limits, especially given the growing challenges.
Traditional cognitive health
assessments have their place…
...but these approaches have limits,
especially given the growing challenges.
MONTREAL COGNITIVE ASSESSMENT (MoCA)
Time-tested
Can be impacted by patient behavior
Fast to administer and evaluate
Valid for only certain populations9
High sensitivity for MCI4,5
Low specificity10,11
FULL NEUROPSYCHOLOGICAL BATTERIES
Comprehensive, assesses multiple domains6
Can be impacted by patient behavior
High reliability and validity in MCI7,8 and TBI7
Slower to administer12
Long lead time to receive analysis12
4. Nasreddine et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. 2005
5. Smith et al. The Montreal Cognitive Assessment: Validity and Utility in a Memory Clinic Setting. 2007
6. Roebuck-Spencer et al. Cognitive Screening Tests Versus Comprehensive Neuropsychological Test Batteries. 2017
7. Liew. Developing a Brief Neuropsychological Battery for Early Diagnosis of Cognitive Impairment. 2019
8. Jacova et al. Neuropsychological Testing and Assessment for Dementia. 2007
9. Hobson. The Montreal Cognitive Assessment (MoCA). 2015
10. Dautzenberg et al. Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry. 2020
11. Davis et al. Montreal Cognitive Assessment (MoCA) for the detection of dementia. 2021
12. Roebuck-Spencer et al. Cognitive Screening Tests Versus Comprehensive Neuropsychological Test Batteries. 2017
5. Smith et al. The Montreal Cognitive Assessment: Validity and Utility in a Memory Clinic Setting. 2007
6. Roebuck-Spencer et al. Cognitive Screening Tests Versus Comprehensive Neuropsychological Test Batteries. 2017
7. Liew. Developing a Brief Neuropsychological Battery for Early Diagnosis of Cognitive Impairment. 2019
8. Jacova et al. Neuropsychological Testing and Assessment for Dementia. 2007
9. Hobson. The Montreal Cognitive Assessment (MoCA). 2015
10. Dautzenberg et al. Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry. 2020
11. Davis et al. Montreal Cognitive Assessment (MoCA) for the detection of dementia. 2021
12. Roebuck-Spencer et al. Cognitive Screening Tests Versus Comprehensive Neuropsychological Test Batteries. 2017
Overcome these limitations
with VoxNeuro CORE brain performance software.
Find out more about how
VoxNeuro CORE works in your practice.
© 2019-2023 VoxNeuro Inc. All Rights Reserved
VoxNeuro is registered with the FDA and Health Canada. VoxNeuro is available to be deployed and used in any clinical setting in the US and Canada.
Intended Use: CHAMP is a Computerized Cognitive Assessment Aid, a software device that uses neurophysiological output values from a battery of cognitive tasks that are generated during a Cognitive Health Assessment™ to provide an interpretation of cognitive function.
Indications for Use: CHAMP is indicated as an adjunctive tool for evaluating cognitive function, including memory, information processing, attention and concentration, in individuals aged 12-90 years of age on a single occasion or over periodic assessments. Results should be interpreted only by qualified healthcare professionals.
Warnings: CHAMP is not a standalone diagnostic device. CHAMP is not intended to be used to identify the presence or absence of clinical diagnoses.
VoxNeuro is registered with the FDA and Health Canada. VoxNeuro is available to be deployed and used in any clinical setting in the US and Canada.
Intended Use: CHAMP is a Computerized Cognitive Assessment Aid, a software device that uses neurophysiological output values from a battery of cognitive tasks that are generated during a Cognitive Health Assessment™ to provide an interpretation of cognitive function.
Indications for Use: CHAMP is indicated as an adjunctive tool for evaluating cognitive function, including memory, information processing, attention and concentration, in individuals aged 12-90 years of age on a single occasion or over periodic assessments. Results should be interpreted only by qualified healthcare professionals.
Warnings: CHAMP is not a standalone diagnostic device. CHAMP is not intended to be used to identify the presence or absence of clinical diagnoses.